Objective: The aim of this study was to investigate the effects of chemohormonal therapy on catalase (CAT), superoxidedismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), arylesterase (ARE), paraoxonase (PON), myeloperoxidase(MPO), malondialdehyde (MDA), total antioxidant status (TAS), total oxidant status (TOS) in patients with metastaticcastration-resistant prostate cancer (MCCRPC). The aim of this study was to investigate the effect of chemohormonal treatmentand treatment resistance on oxidant and antioxidant system in cancer and prostate cancer through oxidative stress index (OSI)parameters and to show that it may have a predictive value in the diagnosis, prognosis and treatment of the disease. Materialand method: This study included 112 patients diagnosed with prostate cancer and 30 healthy individuals (control group) whowere admitted to the Departments of Medical Oncology and Radiation Oncology of Atatürk University Medical FacultyHospital. Patients were divided into four groups according to the treatment protocol. Patients received androgen suppressiontherapy, secondary hormone therapy and non-hormone therapy (chemoteropathic drugs) respectively (as resistancedeveloped). The first group was sensitive to androgen suppression therapy (ADT), the second group was resistant to androgensuppression therapy and sensitive to chemotherapeutic agents. The third group was the group that developed resistance tochemotherapeutics. The fourth group was patients who were diagnosed with prostate cancer and did not receive treatment.CAT, SOD, tGSH, GPx, GPx, ARE, PON, MPO and MDA levels were analyzed by manual antioxidant methods in patient andcontrol serum samples, while TAS, TOS and OSI levels were analyzed by commercially purchased kits and according to the Erelmethod. Results: CAT, ARE, MPO, TAS, TOS and OSI parameters showed significant differences between the groups (p
Kökpınar et al. (Mon,) studied this question.